Durvalumab (MEDI4736) in Hypermutated Metastatic Castration-Resistant Prostate Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Durvalumab (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 12 Jan 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 27 Nov 2017 Planned End Date changed from 15 Nov 2022 to 15 May 2023.
- 27 Nov 2017 Planned primary completion date changed from 15 Nov 2022 to 15 May 2023.